Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo + Yervoy
nivolumab + ipilimumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with unresectable or metastatic hepatocellular carcinoma who previously received sorafenib.
LAMPGEN ANALYSIS
Why it matters
The same supplement that added first-line use fulfilled the confirmatory requirement for the earlier post-sorafenib accelerated indication.
What research teams should watch
Document prior sorafenib exposure and distinguish this conversion from the simultaneous first-line label extension.
PRIMARY RECORDS